M. Sant, C. Allemani, C. Tereanu, D. Angelis, R. Capocaccia et al., Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project, Blood, vol.116, issue.19, 2010.
DOI : 10.1182/blood-2010-05-282632

E. Mckelvey, J. Gottlieb, H. Wilson, A. Haut, R. Talley et al., Hydroxyldaunomycin (adriamycin) combination chemotherapy in malignant lymphoma, Cancer, vol.12, issue.4, pp.1484-93, 1976.
DOI : 10.1002/1097-0142(197610)38:4<1484::AID-CNCR2820380407>3.0.CO;2-I

B. Coiffier, E. Lepage, J. Brière, R. Herbrecht, H. Tilly et al., CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma, New England Journal of Medicine, vol.346, issue.4, pp.235-277, 2002.
DOI : 10.1056/NEJMoa011795

M. Pfreundschuh, L. Trümper, A. Österborg, R. Pettengell, M. Trneny et al., CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group, The Lancet Oncology, vol.7, issue.5, pp.379-91, 2006.
DOI : 10.1016/S1470-2045(06)70664-7

O. Fitoussi, K. Belhadj, N. Mounier, M. Parrens, H. Tilly et al., Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA, Haematologica, vol.96, issue.8, pp.1136-1179, 2011.
DOI : 10.3324/haematol.2010.038109

A. Italiano, F. Jardin, F. Peyrade, L. Saudes, H. Tilly et al., Adapted CHOP plus rituximab in non-Hodgkin's lymphoma in patients over 80 years old, Haematologica, vol.90, issue.9, pp.1281-1284, 2005.

T. Habermann, E. Weller, V. Morrison, R. Gascoyne, P. Cassileth et al., Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma, Journal of Clinical Oncology, vol.24, issue.19, pp.3121-3128, 2006.
DOI : 10.1200/JCO.2005.05.1003

M. Pfreundschuh, J. Schubert, M. Ziepert, R. Schmits, M. Mohren et al., Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60), The Lancet Oncology, vol.9, issue.2, pp.105-121, 2008.
DOI : 10.1016/S1470-2045(08)70002-0

R. Epelbaum, D. Faraggi, Y. Ben-arie, M. Ben-shahar, N. Haim et al., Survival of diffuse large cell lymphoma. A multivariate analysis including dose intensity variables, Cancer, vol.8, issue.6, pp.1124-1133, 1990.
DOI : 10.1002/1097-0142(19900915)66:6<1124::AID-CNCR2820660608>3.0.CO;2-T

A. Bosly, D. Bron, A. Van-hoof, D. Bock, R. Berneman et al., Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP, Annals of Hematology, vol.102, issue.4, pp.277-83, 2008.
DOI : 10.1007/s00277-007-0399-y

E. Lepage, C. Gisselbrecht, C. Haioun, C. Sebban, H. Tilly et al., Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: Application to LNH-87 protocol, Annals of Oncology, vol.4, issue.8, pp.651-657, 1993.
DOI : 10.1093/oxfordjournals.annonc.a058619

R. Pettengell, M. Schwenkglenks, and A. Bosly, Association of reduced relative dose intensity and survival in lymphoma patients receiving CHOP-21 chemotherapy, Annals of Hematology, vol.104, issue.5
DOI : 10.1007/s00277-008-0447-2

Y. Terada, H. Nakamae, R. Aimoto, H. Kanashima, E. Sakamoto et al., Impact of relative dose intensity (RDI) in CHOP combined with rituximab (R-CHOP) on survival in diffuse large B-cell lymphoma, Journal of Experimental & Clinical Cancer Research, vol.28, issue.1, pp.116-126, 2009.
DOI : 10.1186/1756-9966-28-116

T. Hirakawa, H. Yamaguchi, N. Yokose, S. Gomi, K. Inokuchi et al., Importance of maintaining the relative dose intensity of CHOP-like regimens combined with rituximab in patients with diffuse large B-cell lymphoma, Annals of Hematology, vol.24, issue.19, pp.897-904, 2010.
DOI : 10.1007/s00277-010-0956-7

R. Epelbaum, N. Haim, M. Ben-shahar, R. Y. Cohen, and Y. , Dose-intensity analysis for CHOP chemotherapy in diffuse aggressive large cell lymphoma, Isr J Med Sci, vol.24, pp.9-10533, 1988.

L. Kwak, J. Halpern, R. Olshen, and S. Horning, Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis., Journal of Clinical Oncology, vol.8, issue.6, pp.963-77, 1990.
DOI : 10.1200/JCO.1990.8.6.963

H. Wildiers and M. Reiser, Relative dose intensity of chemotherapy and its impact on outcomes in patients with early breast cancer or aggressive lymphoma, Critical Reviews in Oncology/Hematology, vol.77, issue.3, pp.221-261, 2011.
DOI : 10.1016/j.critrevonc.2010.02.002

N. Roswall, A. Olsen, J. Christensen, K. Rugbjerg, and L. Mellemkjaer, Social inequality and incidence of and survival from Hodgkin lymphoma, non-Hodgkin lymphoma and leukaemia in a population-based study in Denmark, 1994???2003, European Journal of Cancer, vol.44, issue.14, pp.2058-73, 1994.
DOI : 10.1016/j.ejca.2008.06.011

D. Cronin-fenton, L. Sharp, S. Deady, and H. Comber, Treatment and survival for non-Hodgkin???s lymphoma: Influence of histological subtype, age, and other factors in a population-based study (1999???2001), European Journal of Cancer, vol.42, issue.16, pp.2786-93, 1999.
DOI : 10.1016/j.ejca.2006.04.018

B. Frederiksen, S. Dalton, M. Osler, M. Steding-jessen, and B. De-nully, Socioeconomic position, treatment, and survival of non-Hodgkin lymphoma in Denmark ??? a nationwide study, British Journal of Cancer, vol.9, issue.5, pp.988-95, 2012.
DOI : 10.1038/bjc.2012.3

L. Tao, J. Foran, C. Clarke, S. Gomez, and T. Keegan, Socioeconomic disparities in mortality after diffuse large B-cell lymphoma in the modern treatment era, Blood, vol.123, issue.23, pp.3553-62, 2014.
DOI : 10.1182/blood-2013-07-517110

F. Loberiza, A. Cannon, D. Weisenburger, J. Vose, M. Moehr et al., Survival Disparities in Patients With Lymphoma According to Place of Residence and Treatment Provider: A Population-Based Study, Journal of Clinical Oncology, vol.27, issue.32, pp.5376-82, 2009.
DOI : 10.1200/JCO.2009.22.0038

C. Pornet, C. Delpierre, O. Dejardin, P. Grosclaude, L. Launay et al., Construction of an adaptable European transnational ecological deprivation index: the French version, Journal of Epidemiology and Community Health, vol.66, issue.11, 2011.
DOI : 10.1136/jech-2011-200311

J. Blay, F. Gomez, C. Sebban, T. Bachelot, P. Biron et al., The international prognostic index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial, Blood, vol.92, issue.10, pp.3562-3570, 1998.

L. Sehn, B. Berry, M. Chhanabhai, C. Fitzgerald, K. Gill et al., The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP, Blood, vol.109, issue.5, pp.1857-61, 2007.
DOI : 10.1182/blood-2006-08-038257

F. Peyrade, F. Jardin, C. Thieblemont, A. Thyss, J. Emile et al., Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial, The Lancet Oncology, vol.12, issue.5, pp.460-468, 2011.
DOI : 10.1016/S1470-2045(11)70069-9

G. Lyman, D. Dale, J. Friedberg, J. Crawford, and R. Fisher, Incidence and Predictors of Low Chemotherapy Dose-Intensity in Aggressive Non-Hodgkin's Lymphoma: A Nationwide Study, Journal of Clinical Oncology, vol.22, issue.21, pp.4302-4313, 2004.
DOI : 10.1200/JCO.2004.03.213

G. Bonadonna and P. Valagussa, Dose-Response Effect of Adjuvant Chemotherapy in Breast Cancer, New England Journal of Medicine, vol.304, issue.1, pp.10-15, 1981.
DOI : 10.1056/NEJM198101013040103

W. Hryniuk and H. Bush, The importance of dose intensity in chemotherapy of metastatic breast cancer., Journal of Clinical Oncology, vol.2, issue.11, pp.1281-1289, 1984.
DOI : 10.1200/JCO.1984.2.11.1281

J. Green, A. Dawson, L. Fell, and S. Murray, Measurement of drug dosage intensity in MVPP therapy in Hodgkin's disease., British Journal of Clinical Pharmacology, vol.131, issue.5, pp.511-515, 1980.
DOI : 10.1111/j.1365-2125.1980.tb05847.x

L. Berben, F. Dobbels, S. Engberg, M. Hill, D. Geest et al., An Ecological Perspective on Medication Adherence, Western Journal of Nursing Research, vol.34, issue.5, pp.635-53, 2012.
DOI : 10.1177/0193945911434518

G. Compaci, L. Ysebaert, L. Obéric, H. Derumeaux, and G. Laurent, Effectiveness of telephone support during chemotherapy in patients with diffuse large B cell lymphoma: The Ambulatory Medical Assistance (AMA) experience, International Journal of Nursing Studies, vol.48, issue.8, pp.926-958, 2011.
DOI : 10.1016/j.ijnurstu.2011.01.008

L. Noens, M. Van-lierde, D. Bock, R. Verhoef, G. Zachee et al., Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study, Blood, vol.113, issue.22, pp.5401-5412, 2008.
DOI : 10.1182/blood-2008-12-196543

F. Despas, H. Roche, and G. Laurent, Anticancer drug adherence], Bull Cancer, vol.100, issue.5, pp.473-84, 2013.

S. Schleifer, S. Bhardwaj, A. Lebovits, J. Tanaka, M. Messe et al., Predictors of physician nonadherence to chemotherapy regimens, Cancer, vol.42, issue.4, pp.945-51, 1991.
DOI : 10.1002/1097-0142(19910215)67:4<945::AID-CNCR2820670415>3.0.CO;2-R

H. Yamaguchi, T. Hirakawa, and K. Inokuchi, Importance of Relative Dose Intensity in Chemotherapy for Diffuse Large B-Cell Lymphoma, Journal of Clinical and Experimental Hematopathology, vol.51, issue.1, 2011.
DOI : 10.3960/jslrt.51.1

M. Maurer, H. Ghesquières, J. Jais, T. Witzig, C. Haioun et al., Event-Free Survival at 24 Months Is a Robust End Point for Disease-Related Outcome in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy, Journal of Clinical Oncology, vol.32, issue.10
DOI : 10.1200/JCO.2013.51.5866

B. Lee, O. Goktepe, K. Hay, J. Connors, L. Sehn et al., Effect of Place of Residence and Treatment on Survival Outcomes in Patients With Diffuse Large B-Cell Lymphoma in British Columbia, The Oncologist, vol.19, issue.3, pp.283-90, 2014.
DOI : 10.1634/theoncologist.2013-0343

O. Dejardin, C. Berchi, A. Mignon, C. Pornet, E. Guillaume et al., In??galit??s sociales, de sant?? du constat ?? l???action???????Int??r??t de la mise en place d???un accompagnement personnalis?? pour la r??duction des in??galit??s sociales en canc??rologie, Revue d'??pid??miologie et de Sant?? Publique, vol.59, issue.1, pp.45-51, 2011.
DOI : 10.1016/j.respe.2010.10.008

C. Pornet, O. Dejardin, F. Morlais, V. Bouvier, and G. Launoy, Socioeconomic determinants for compliance to colorectal cancer screening. A multilevel analysis, Journal of Epidemiology & Community Health, vol.64, issue.4, pp.318-342, 2010.
DOI : 10.1136/jech.2008.081117
URL : https://hal.archives-ouvertes.fr/inserm-00421598